Certified by Founder Lodge
Rock Springs Capital
United States - Baltimore, Maryland
INVESTOR
1 Disclosed Funding Rounds $135,000,000
6 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Rock Springs Capital is an investment firm that manages long-biased, healthcare-focused public equity funds.
| Company | Date | Round | Raised |
|---|---|---|---|
 Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
 Genesis Therapeutics |
August, 22 ,2023 | Series B | $200,000,000 |
 Apollo Therapeutics |
September, 11 ,2023 | Series C | $226,500,000 |
 Avalyn Pharma Inc. |
September, 28 ,2023 | Series C | $175,000,000 |
 FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
 Arsenal Biosciences, Inc. |
September, 04 ,2024 | Series C | $325,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
